{"id":"iva","safety":{"commonSideEffects":[{"rate":"27","effect":"Headache"},{"rate":"25","effect":"Upper respiratory tract infection"},{"rate":"15","effect":"Nausea"},{"rate":"14","effect":"Diarrhea"},{"rate":"12","effect":"Rash"},{"rate":"11","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25","title":"KALYDECO (IVACAFTOR) TABLET, FILM COATED KALYDECO (IVACAFTOR) GRANULE [VERTEX PHARMACEUTICALS INCORPORATED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVA (ivacaftor) binds directly to the CFTR protein and increases the likelihood that the channel will remain open, allowing more chloride ions to flow across cell membranes. This corrects the defective ion transport characteristic of cystic fibrosis, particularly in patients with gating mutations. By restoring CFTR function, ivacaftor improves mucociliary clearance and reduces airway inflammation.","oneSentence":"IVA is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator protein to enhance chloride ion transport.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:31.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D)"},{"name":"Cystic fibrosis in combination with lumacaftor in patients with F508del-CFTR mutations"}]},"trialDetails":[{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":"Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT05668741","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-02-27","conditions":"Cystic Fibrosis","enrollment":39},{"nctId":"NCT02734537","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-11-23","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT04726501","phase":"PHASE4","title":"CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2018-04-01","conditions":"Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT00421096","phase":"PHASE2","title":"Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2005-05","conditions":"Uterine Cervical Cancer","enrollment":19},{"nctId":"NCT05845749","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-09-25","conditions":"MPS IVA, MPS VI","enrollment":6},{"nctId":"NCT07349394","phase":"PHASE1","title":"Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-01-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT07451665","phase":"PHASE4","title":"Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2026-04-01","conditions":"Takayasu Arteritis (TAK)","enrollment":180},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT06746428","phase":"NA","title":"Activity Coaching During Pelvic Radiation Therapy","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-01-27","conditions":"Radiation Therapy, Gynecologic Cancer, Exercise Therapy","enrollment":16},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT07380256","phase":"NA","title":"Visual Influences on Vestibular Adaptation","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-02","conditions":"Vestibular Hypofunction, Binocular Vision Abnormalities, Reduced Vision","enrollment":100},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT07418931","phase":"PHASE2","title":"A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-05","conditions":"Advanced Squamous Non-Small Cell Lung Cancer","enrollment":108},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT07400094","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC","status":"NOT_YET_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2026-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm","enrollment":50},{"nctId":"NCT05844449","phase":"PHASE3","title":"Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older","status":"ENROLLING_BY_INVITATION","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-08-11","conditions":"Cystic Fibrosis","enrollment":174},{"nctId":"NCT06319963","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Theravectys S.A.","startDate":"2024-08-08","conditions":"HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":72},{"nctId":"NCT07361536","phase":"","title":"Cardiac Structure and Function in MPS","status":"RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2025-09-01","conditions":"MPS I, MPS IV A, MPS - Mucopolysaccharidosis","enrollment":240},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT02819752","phase":"PHASE1","title":"PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-07-12","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT01025089","phase":"PHASE2","title":"Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-12","conditions":"Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA","enrollment":18},{"nctId":"NCT03734809","phase":"PHASE2","title":"NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2019-05-03","conditions":"NPC","enrollment":43},{"nctId":"NCT07245381","phase":"PHASE1, PHASE2","title":"Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation","status":"NOT_YET_RECRUITING","sponsor":"Dr. Itay GoorAryeh","startDate":"2025-12","conditions":"Cervix Cancer","enrollment":65},{"nctId":"NCT02595879","phase":"PHASE1","title":"Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-09-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT03738228","phase":"PHASE1","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-07","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT05422222","phase":"PHASE3","title":"Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-06-21","conditions":"Cystic Fibrosis","enrollment":210},{"nctId":"NCT00977574","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":349},{"nctId":"NCT03634267","phase":"PHASE1","title":"MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-03","conditions":"Human Papillomavirus-Related Carcinoma, Human Papillomavirus-Related Cervical Carcinoma, Stage IB2 Cervical Cancer AJCC v8","enrollment":26},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06460506","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-11-21","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT06056310","phase":"PHASE1","title":"Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-01-18","conditions":"Head and Neck Cancer","enrollment":18},{"nctId":"NCT06299709","phase":"PHASE1","title":"A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-13","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":"Cystic Fibrosis","enrollment":82},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":"Cystic Fibrosis","enrollment":507},{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05444257","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-08","conditions":"Cystic Fibrosis","enrollment":822},{"nctId":"NCT03765918","phase":"PHASE3","title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-17","conditions":"Head and Neck Neoplasms","enrollment":714},{"nctId":"NCT01747304","phase":"","title":"Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2012-07","conditions":"Atypical Femur Fracture","enrollment":285},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT05980598","phase":"PHASE2","title":"TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Ascendis Pharma A/S","startDate":"2023-09-29","conditions":"Head and Neck Neoplasms","enrollment":27},{"nctId":"NCT07036848","phase":"","title":"Efficacy and Safety of Surgical Treatment for Type IVa CBD","status":"RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-07-14","conditions":"Choledochal Cyst","enrollment":1500},{"nctId":"NCT06495138","phase":"NA","title":"Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-21","conditions":"Multiple Sclerosis","enrollment":138},{"nctId":"NCT05002751","phase":"","title":"Quantifying Radiation Induced Vaginal Stenosis","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2022-10-06","conditions":"Vaginal Stricture, Vaginal Stenosis","enrollment":12},{"nctId":"NCT01439854","phase":"NA","title":"Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-03","conditions":"Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome","enrollment":18},{"nctId":"NCT06873204","phase":"NA","title":"Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Purdue University","startDate":"2025-07","conditions":"Healthy","enrollment":25},{"nctId":"NCT07028918","phase":"EARLY_PHASE1","title":"A Prospective Single-Arm Study（NCLDR）","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-08-30","conditions":"Oral Squamous Cell Carcinoma (OSCC)","enrollment":35},{"nctId":"NCT05187624","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-04-05","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT05284006","phase":"","title":"Non-invasive Functional Assessment and Pathogenesis of Morquio A","status":"RECRUITING","sponsor":"Nemours Children's Clinic","startDate":"2021-05-01","conditions":"Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA","enrollment":60},{"nctId":"NCT03944265","phase":"NA","title":"Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2019-02-08","conditions":"Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative","enrollment":14},{"nctId":"NCT02854215","phase":"NA","title":"Cost Utility of Radical Surgery in Ovarian Cancer","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-01-18","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT05947513","phase":"NA","title":"Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial","status":"RECRUITING","sponsor":"Addis Ababa University","startDate":"2025-04-10","conditions":"Cervical Cancer","enrollment":27},{"nctId":"NCT06752239","phase":"PHASE3","title":"Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2025-01-01","conditions":"Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases","enrollment":474},{"nctId":"NCT03527264","phase":"PHASE2","title":"BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2018-11-08","conditions":"Cervical Cancer","enrollment":4},{"nctId":"NCT06858254","phase":"PHASE1, PHASE2","title":"Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism","status":"NOT_YET_RECRUITING","sponsor":"Apeiron Research Center","startDate":"2025-04-01","conditions":"Atypical Parkinsonism, Parkinson Disease (PD)","enrollment":60},{"nctId":"NCT02322060","phase":"","title":"In Vitro Activation of Dormant Follicles for Patients with Primary Ovarian Insufficiency","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2014-09","conditions":"In Vitro Activation, Dormant Follicle, Primary Ovarian Insufficiency","enrollment":100},{"nctId":"NCT01898494","phase":"PHASE2","title":"Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-01-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":519},{"nctId":"NCT06011850","phase":"","title":"Investigation of the Effects of Quadratus Lumborum Block Applied to Patients in Kidney Transplant Surgery","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2023-10-03","conditions":"Kidney Transplant Recipient, Kidney Transplant Donor","enrollment":94},{"nctId":"NCT01220583","phase":"PHASE2","title":"Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-01","conditions":"Head and Neck Cancer","enrollment":252},{"nctId":"NCT05834712","phase":"NA","title":"Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-05-11","conditions":"Nasopharyngeal Carcinoma","enrollment":224},{"nctId":"NCT05619900","phase":"","title":"Registry of Patients Diagnosed With Lysosomal Storage Diseases","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-05-31","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis IV A","enrollment":250},{"nctId":"NCT01566240","phase":"PHASE3","title":"Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2012-11-08","conditions":"Cervical Cancer","enrollment":500},{"nctId":"NCT01554397","phase":"PHASE2, PHASE3","title":"Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-10-13","conditions":"Cervical Cancer","enrollment":101},{"nctId":"NCT04931173","phase":"NA","title":"Mechanical Bowel Prep Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-03","conditions":"Colorectal Surgery","enrollment":1062},{"nctId":"NCT03277196","phase":"PHASE3","title":"A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-08-16","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT06611150","phase":"PHASE1","title":"Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":24},{"nctId":"NCT04235140","phase":"PHASE3","title":"Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-24","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT03459079","phase":"PHASE2","title":"Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-08-14","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)","enrollment":128},{"nctId":"NCT06575322","phase":"","title":"Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-09-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":302},{"nctId":"NCT06576180","phase":"","title":"Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-08-23","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":306},{"nctId":"NCT04840862","phase":"PHASE4","title":"Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-05-09","conditions":"Drug Drug Interaction","enrollment":6},{"nctId":"NCT06100497","phase":"PHASE2","title":"Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2023-10-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT06232967","phase":"","title":"PPIO-006 Primary Tumor Resection for IVa NSCLC","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-04-01","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":223},{"nctId":"NCT06478264","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhangzhou Municipal Hospital","startDate":"2024-07-13","conditions":"Esophageal Small Cell Carcinoma","enrollment":40},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT06419673","phase":"PHASE2","title":"Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Cervical Cancer","enrollment":240},{"nctId":"NCT06299696","phase":"PHASE1","title":"A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-26","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT06396143","phase":"","title":"Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-07-01","conditions":"Locally Advanced Gastric Carcinoma","enrollment":120},{"nctId":"NCT03537651","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-04-25","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT03601507","phase":"PHASE2","title":"Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2019-03-11","conditions":"CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7","enrollment":9},{"nctId":"NCT06268600","phase":"NA","title":"The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2019-01-01","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Hypothyroidism","enrollment":320},{"nctId":"NCT05280314","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","status":"RECRUITING","sponsor":"IO Biotech","startDate":"2023-12-21","conditions":"Melanoma, Squamous Cell Carcinoma of Head and Neck","enrollment":60},{"nctId":"NCT00019006","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-03","conditions":"Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer","enrollment":""},{"nctId":"NCT00020267","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Metastatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-07","conditions":"Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer","enrollment":""},{"nctId":"NCT06282536","phase":"PHASE2","title":"Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-03","conditions":"Potentially Resectable ALK Positive Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT02609386","phase":"PHASE2","title":"IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity","status":"COMPLETED","sponsor":"Brooklyn ImmunoTherapeutics, LLC","startDate":"2016-01-11","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":105},{"nctId":"NCT06058195","phase":"","title":"Comparison of Quadratus Lumborum and Transverse Abdominis Plane Blocks With Intravenous Analgesic in Gallbladder Surgery","status":"UNKNOWN","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2023-10-03","conditions":"Cholecystectomy","enrollment":128},{"nctId":"NCT03445793","phase":"","title":": TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2018-03-01","conditions":"Cystic Fibrosis (CF)","enrollment":5},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":"Cystic Fibrosis","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10163,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VX-770","ivacaftor","Ivacaftor","ivacaftor; VX-770","Kalydeco"],"phase":"marketed","status":"active","brandName":"IVA","genericName":"IVA","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IVA is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator protein to enhance chloride ion transport. Used for Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D), Cystic fibrosis in combination with lumacaftor in patients with F508del-CFTR mutations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}